Categories: News

DoubleLine Foresees Further Treasury Yield Curve Steepening, Risk of Elevated Term Premium

TAMPA, Fla., Oct. 3, 2025 /PRNewswire/ — The U.S. Treasury yield curve, DoubleLine Global Bond Portfolio Manager Bill Campbell writes in a new research paper, likely will steepen further under the effects of both federal funds rate cuts on short-term interest rates and fiscal pressures elevating the term premium embedded in longer-term Treasury yields.

- Advertisement -

The paper, titled “Yield Curve Steepening in the Near Term, Risk of Higher Term Premium Further Out,” can be downloaded here: https://doubleline.com/wp-content/uploads/DoubleLine_Yield-Curve-Term-Premium_September-2025.pdf

- Advertisement -

“In this cycle and beyond,” Mr. Campbell writes, DoubleLine’s “investment team will remain vigilant for upward fiscal, monetary and political pressures that risk escalating the term premium embedded in Treasury rates. For reasons which I’ll outline below, political gridlock in Washington, D.C., including the Oct. 1 shutdown of nonessential government operations, does not alter this outlook.”

- Advertisement -

The key risk “to the steepener trade,” according to Mr. Campbell, “would be a change in the Fed’s balance sheet policy. In June 2022, the Fed resumed engaged in QT by reducing its holdings of Treasury securities and Agency mortgage-backed securities…. To date, the Fed has maintained a resolute focus on a careful balancing of inflation and employment mandates. However, given the policy preferences aggressively pursued by the White House, the possibility one day of a politicized Fed bent on yield curve control cannot be dismissed for the future.”

- Advertisement -

Mr. Campbell joined DoubleLine in 2013. He oversees the firm’s Global Sovereign Debt team and serves as a Portfolio Manager of the DoubleLine Emerging Markets Local Currency and Global Bond strategies. He is a permanent member of the Fixed Income Asset Allocation Committee. He holds a B.S. in Business Economics and International Business, as well as a B.A. in English, from Pennsylvania State University. Mr. Campbell holds an M.A. in Mathematics, with a focus on Mathematical Finance, from Boston University.

- Advertisement -

About DoubleLine

- Advertisement -

DoubleLine Capital LP is an investment adviser registered under the Investment Advisers Act of 1940. DoubleLine’s offices can be reached by telephone at (813) 791-7333 or by email at info@doubleline.com. In addition to its headquarters in Tampa, FL, and an office in Los Angeles, DoubleLine has offices in Dubai, London and Tokyo. Media can reach DoubleLine by email at media@doubleline.com.

- Advertisement -

DoubleLine® is a registered trademark of DoubleLine Capital LP.

- Advertisement -

Logo – https://mma.prnewswire.com/media/752903/DoubleLine_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/doubleline-foresees-further-treasury-yield-curve-steepening-risk-of-elevated-term-premium-302574556.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

3 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

3 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

3 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

3 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

3 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

3 hours ago